Open access
Sep 2026
Venetoclax-based Therapy Improves Outcomes across the Evolving Biology of t(11;14) Multiple Myeloma
Clinical benefit was greatest when venetoclax was administered earlier, preceding the emergence of transcriptomic reprogramming that reduces BCL2 dependency, and findings support transcriptomic biomarker guided, subtype specific venetoclax based treatment strategies to optimize outcomes in patients with t(11;14) MM.
P. Sudalagunta, Filip Ionescu, R. Canevarolo et al.
· medRxiv · 0 citations